Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1994-07-08
2001-08-21
Witz, Jean C. (Department: 1651)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S381000, C530S383000, C530S384000, C424S529000, C424S094640, C514S002600
Reexamination Certificate
active
06277961
ABSTRACT:
The invention relates to a fibrinogen solution which is suitable for use in a tissue adhesive and can be stored at temperatures between +4° C. and +25° C. for at least four weeks without loss of its ability to function, in particular without significant change in consistency and coagulation properties.
Fibrin has been used for gluing tissues and for stopping bleeding for a long time. It is employed, for example, for sealing large-area bleeding, for uniting tissue in parenchymal organs, for conjuctival bonding or for securing sutures and stopping bleeding after various surgical interventions. The essential advantage compared with other methods (for example bonding with synthetic tissue adhesives) is the use of physiological substances which have high biocompatibility and a beneficial effect on wound healing. In tissue bonding, the final phase of blood coagulation is imitated: fibrinogen, which contains factor XIII, is brought into contact with thrombin and calcium ions on the area to be bonded. Thrombin cleaves the fibrinopeptides A and B from fibrinogen, resulting in fibrin monomers which form a soluble fibrin clot. At the same time, the transglutaminase factor XIII is activated by thrombin and calcium ions, and it stabilizes the clot by crosslinking the fibrin monomers. An increased resistance of the clot to fibrinolysis can be achieved if required by adding a plasmin inhibitor to the fibrinogen or thrombin solution.
On the one hand commercial products are available for tissue bonding with fibrin adhesives, and on the other hand it is also possible for the user to prepare fibrin adhesives as required (WO 86/01814).
The commercially obtainable fibrin adhesives are two-component adhesives in which the first component contains fibrinogen, factor XIII and aprotinin, and the second contains thrombin and calcium ions. The components are in either deep-frozen or freeze-dried form. One disadvantage of these products is the need to prepare the adhesive ready for use, since both the thawing and warming to the use temperature, and the dissolving of the lyophilisates take, owing to the high fibrinogen concentration of about 6-10%, a relatively long time. Another considerable disadvantage is the relatively short stability (about 4 hours) of the adhesive components ready for use. If there are unenvisaged delays between preparation and use, the fibrin adhesive can thus become unusable or lose efficacy.
Fibrinogen concentrates can also be prepared as required by the user himself, by various methods, and combined with commercially obtainable thrombin products to give a tissue adhesive. This procedure is, however, associated with the following serious disadvantages: in order to rule out the transmission of viruses, it is possible to use only blood from the patient to be treated for obtaining the fibrinogen concentrate. Since the preparation of the concentrate is labor-intensive and time-consuming, application is not possible in cases of emergency. Furthermore, a constant composition and quality of the fibrinogen concentrate is not ensured when blood from a single donor is used.
Because of the stated disadvantages both of the commercial fibrinogen concentrates and of those prepared by the user himself, there is a need for a fibrinogen concentrate which has maximum stability in the form ready for use (thawed or dissolved). The fibrinogen concentrate according to the invention eliminates both the disadvantages of previous tisse adhesives. One advantage is more rapid availability because no time needs to be spent thawing or dissolving the fibrinogen component. Another advantage is that the dissolved fibrinogen component remains able to function over a lengthy period and does not have to be discarded if an intended bonding is not carried out.
The object of the invention is therefore to provide a fibrinogen concentrate which can be stored at +4° C. to +25° C. for at least 4 weeks without loss of the ability to function. In particular a solution of this type should be useful as a component of a tissue adhesive.
EP 0,103,196 describes the preparation of a fibrinogen concentrate from cryoprecipitate which, after thawing and dilution, has been treated with 2.5% Al(OH)
3
. The concentrate is freeze-dried for stabilization and is stable for 4 h after reconstitution.
EP 0,085,923 describes the preparation of an arginine-containing fibrinogen concentrate which remains stable for a working day.
Surprisingly, a process for preparing a fibrinogen solution which can be stored for a lengthy period with negligible loss of coagulability and thus of its suitability for tissue bonding has now been found. The process comprises subjecting a fibrinogen solution to at least two adsorption steps.
A solution treated in this way can be stored for a lengthy period without losing its ability to function even after thawing from the deep-frozen state or after dissolving from the freeze-dried state.
The invention therefore relates to a fibrinogen solution which can be stored at temperatures between +4° C. and +25° C. for at least four weeks without losing its ability to function, and which can be obtained by treating a fibrinogen solution at least twice with an adsorbent, and obtaining the supernatant each time.
A solution of a cryoprecipitate can be used as fibrinogen solution. A solution of this type can contain 1.5-15%, preferably 5-11%, of coagulable plasma protein.
Adsorbents which can be used are alkaline earth metal salts which are sparingly soluble in water or, preferably, aluminum hydroxide or ion exchangers, preferably anion exchangers.
The concentration of the alkaline earth metal salt or aluminum hydroxide for the adsorption is between 0.05 and 2.5% (weight/volume), preferably 0.05-0.5% (weight/ volume), and the amount of ion exchanger used is 0.5-20g, preferably 3-10 g, per kg of cryoprecipitate.
The fibrinogen solution can, if necessary, be further purified by processes known to the person skilled in the art (for example EP 0,103,196). The fibrinogen solution obtained in this way can be stored as liquid or can be deep-frozen or freeze-dried. The fibrinogen solution or a fibrinogen solution obtained after a frozen solution or after dissolving for a freeze-dried solution can be stored at a temperature from +1° C. to +37° C. Storage is preferably at a temperature from +4° C. to +25° C. A solution according to the invention is stable for at least four weeks.
A stable solution of this type can be used as a component of a fibrin adhesive.
It can contain 10-200, preferably about 60, units of factor XIII.
REFERENCES:
patent: 3849252 (1974-11-01), Percs et al.
patent: 4170590 (1979-10-01), Stephen et al.
patent: 4272523 (1981-06-01), Kotitschke et al.
patent: 4543210 (1985-09-01), Mita et al.
patent: 4627879 (1986-12-01), Rose et al.
patent: 4743680 (1988-05-01), Mathews et al.
patent: 4818291 (1989-04-01), Iwatsuki et al.
patent: 4847362 (1989-07-01), Mathews et al.
patent: 4960757 (1990-10-01), Kumpe et al.
patent: 5099003 (1992-03-01), Kotitschke et al.
patent: 5252709 (1993-10-01), Burnouf et al.
patent: 0 014 333 (1980-08-01), None
patent: 0 085 923 A1 (1983-08-01), None
patent: 0 103 196 (1984-03-01), None
patent: 0 103 196 A2 (1984-03-01), None
patent: 0 305 243 (1989-03-01), None
patent: 0 311 950 (1989-04-01), None
patent: 8912065 (1989-12-01), None
patent: 0416983 (1991-03-01), None
patent: WO 86/01814 (1986-03-01), None
Nadkarni, G.D., et al., “Indian J. Biochem,” vol. 5 (1), 1968, p. 16-18.*
McManama, G., et al., “Blood,” vol. 68(2), 1986, p. 363-371.*
Lawrie, J.S.. et al., Biochemical Society Transactions, vol. 7(4), Aug. 1979, p. 693-694.*
Suzuki:, K.. et al., “A Simple Technique for Purification of Fibrinogen from Plasma by Affinity Chromatography on ristocetin-agarose.” (cited of interest).*
Nadkari, G.D.. et al., Indian J. Biochem., vol. 5(1), p. 16-18, 1968.*
English language abstract of European Patent Application No. 0 305 243 (Mar. 1, 1989).
Hock Johann
Karges Hermann
Aventis Behring GmbH
Finnegan, Henderson Farabow, Garrett and Dunner L.L.P.
Witz Jean C.
LandOfFree
Stable fibrinogen solution does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable fibrinogen solution, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable fibrinogen solution will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2525096